Medications in the GLP-1 class—such as Ozempic, Wegovy, Mounjaro, and Zepbound—are already widely used for diabetes and weight management, but new research points to a much broader clinical impact. A recent analysis from The Washington Post highlights emerging evidence that these therapies may influence multiple chronic conditions beyond their current FDA-approved uses.
Key Areas of Potential Benefit
Research to date identifies 13 areas where GLP-1 medications show varying levels of promise:
- Strongest evidence: Cardiovascular and kidney protection, supported by large clinical trials
- Growing clinical support: Liver disease, sleep apnea, and metabolic-related conditions
- Emerging research: Neurological conditions (including Alzheimer’s), substance use disorders, and inflammatory diseases
- Additional areas under study: Asthma, certain cancers, fertility, PCOS, and appetite regulation (“food noise”)
What This Means for Healthcare Organizations
The expanding scope of GLP-1 therapies reflects a broader shift in how providers understand the connection between metabolic health, inflammation, and chronic disease. While many of these potential benefits are still under investigation, the trend signals:
- Increased demand for GLP-1-related care management and monitoring
- Broader implications for population health strategies
- The need to stay aligned with evolving clinical guidance and coverage policies
Resource: 13 potential benefits of GLP-1s: Report